COMMUNIQUÉS West-GlobeNewswire
-
Oriola Corporation - Repurchase of own shares on 3 August 2017
03/08/2017 - 17:45 -
Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
03/08/2017 - 14:00 -
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
03/08/2017 - 13:30 -
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
03/08/2017 - 13:00 -
Shire plc : Shire reports strong Q2 2017 operating results and cash flow
03/08/2017 - 13:00 -
Changes in Nexstim Plc's Management Team
03/08/2017 - 08:00 -
Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company
03/08/2017 - 07:00 -
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
02/08/2017 - 22:01 -
Advance Notice: Reviewed Financial Statement's announcement for the period 30 June 2017
02/08/2017 - 17:45 -
Oriola Corporation - Repurchase of own shares on 2 August 2017
02/08/2017 - 17:45 -
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
02/08/2017 - 17:00 -
Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus(TM) Surgical Aortic Valve
02/08/2017 - 16:00 -
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
02/08/2017 - 14:00 -
ProMIS Neurosciences Increases Size of Private Placement to $6 Million
02/08/2017 - 13:30 -
Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals
02/08/2017 - 13:00 -
Invivoscribe® lance le test de mutation LeukoStrat® CDx FLT3 sous forme de kit d'essai DVI labellisé CE
02/08/2017 - 10:50 -
Eckert & Ziegler BEBIG : First Half-Year Results 2017 Published
02/08/2017 - 07:45 -
Eckert & Ziegler BEBIG : Publication du résultat du premier semestre 2017
02/08/2017 - 07:45 -
DBV Technologies annonce le lancement d'EPITOPE, étude clinique de phase III d'évaluation de Viaskin Peanut dans le traitement des enfants de 1 à 3 ans atteints d'allergie à l'arachide
02/08/2017 - 07:30
Pages